Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Fish and Richardson
Medtronic
Express Scripts
Julphar
Mallinckrodt
Covington
Harvard Business School
Moodys
Deloitte

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,816,456

« Back to Dashboard

Summary for Patent: 4,816,456
Title: Administration of monoamine acridines in cholinergic neuronal deficit states
Abstract:A method for treating central nervous system or peripheral nervous system cholinergic deficit states such as Alzheimer's disease in a mammal, said method comprising administering to said mammal an amount of a monoamine acridine derivative effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state. The preferred monoamine acridine derivative is 1,2,3,4-tetrahydro-5-aminoacridine. A unit dosage pharmaceutical composition of matter comprising an effective amount of said monoamine acridine derivative sufficient to treat said cholinergic deficit state and a pharmaceutically acceptable inert carrier therefor is also disclosed.
Inventor(s): Summers; William K. (Arcadia, CA)
Assignee:
Application Number:07/098,871
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Compound; Dosage form;

Drugs Protected by US Patent 4,816,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 4,816,456

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 106245 ➤ Try a Free Trial
Australia 621035 ➤ Try a Free Trial
Australia 671933 ➤ Try a Free Trial
Australia 7888694 ➤ Try a Free Trial
Australia 8070787 ➤ Try a Free Trial
Canada 1335813 ➤ Try a Free Trial
Germany 19575031 ➤ Try a Free Trial
Germany 3789967 ➤ Try a Free Trial
Denmark 295888 ➤ Try a Free Trial
European Patent Office 0328535 ➤ Try a Free Trial 96C0021 Belgium ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Federal Trade Commission
Accenture
Farmers Insurance
McKesson
Express Scripts
Julphar
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot